Clinical trialNCT01946880TerminatedPhase 2Interventional

Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment102SLESystemic Lupus Erythematosus

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This trial seeks to describe the effect of withdrawal from mycophenolate mofetil (MMF) on risk of clinically significant disease reactivation in quiescent SLE patients who have been on long-term MMF therapy.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Eliza Chakravarty, MD
Oklahoma Medical Research Foundation
Study Chair
clinicaltrials.gov ↗
Judith A. James, MD, PhD
Oklahoma Medical Research Foundation
Study ChairKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Cedars-Sinai Medical Center
Los Angeles, California, United States
Ucsd
San Diego, California, United States
Ucsf School of Medicine
San Francisco, California, United States
University of Colorado
Denver, Colorado, United States
University of Miami Hospitals and Clinics
Miami, Florida, United States
Emory University
Atlanta, Georgia, United States
University of Chicago
Chicago, Illinois, United States
Brigham & Women'S Hospital
Boston, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
University of Mississippi Medical Center
Jackson, Mississippi, United States
Feinstein Institute for Medical Research
Manhasset, New York, United States
New York University, Langone Medical Center
New York, New York, United States
Weill Cornell Medical College: Hospital for Special Surgery - Rheumatology Division
New York, New York, United States
University of Rochester Medical Center
Rochester, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
the Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma, United States
Penn State University
Hershey, Pennsylvania, United States
Medical University of South Carolina
Charleston, South Carolina, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Hydroxychloroquine or ChloroquineMycophenolate mofetil →Prednisone →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 20 Nov 2013
Primary completion: 3 Jul 2019
Completion: 3 Jul 2019
Last update posted: 17 Aug 2020
Registered enrollment: 102
Registry id: NCT01946880

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.